LONDON, Oct 1 (Reuters) - Roche (ROG.VX: Quote, Profile, Research) is cutting the British price of its lung cancer pill Tarceva as an interim measure to ensure patients get access to the treatment while the country’s healthcare watchdog NICE continues to assess the drug.Roche said on Monday the “unprecedented” temporary programme will subsidise the cost of Tarceva to the state health service, so that the average cost per patient will be the same as the current alternative, Sanofi-Aventis’s (SASY.PA: Quote, Profile, Research) Taxotere.
